Healthcare providers' perceptions and prescribing behaviors of short-term prevention treatment of migraine in the United States.

Healthcare providers (HCPs) play a key role in managing migraine treatments. This study explored HCPs' views and practices regarding short-term prevention (STP) therapies in the US. STP therapies help prevent migraines when patients expect triggers. Over 90% of HCPs believe treatment should allow patients to manage their migraines. Gepants are the most commonly prescribed STP treatment, with rimegepant being the top choice. HCPs consider menstrual migraines and predictable triggers when prescribing STP. The study surveyed HCPs from various backgrounds in August and September 2024. Their responses reveal important insights into how they approach migraine prevention. Understanding these perceptions can help improve treatment strategies for patients. The findings suggest a trend towards more personalized migraine care. Overall, the study highlights the need for better communication between HCPs and patients regarding migraine management options. Clinical relevance: This research highlights the importance of personalized migraine treatment approaches for patients, emphasizing flexibility and consideration of individual triggers in prescribing practices.